The Roche Elecsys anti-HCV II assay provides 100% clinical sensitivity for all known genotypes
Edited by the Laboratorytalk editorial team Apr 6, 2012
Roche has extended its serology panel to include a new generation Elecsys anti-HCV II
With an estimated 216,000 individuals chronically infected in the UK (England 161,000, Northern Ireland 4,000, Scotland 39,000, Wales 12,000), hepatitis C (HCV) remains a major public health problem; and HCV-related end stage liver disease and mortality continue to increase1
The Health Protection Agency states that it is necessary to sustain and enhance efforts to raise awareness, prevent new infections, increase diagnosis, and treat more individuals with infection.
The new Roche Elecsys anti-HCV II assay can play an effective part in this strategy, as it is used to demonstrate the presence of antibodies against HCV during acute and chronic stages of disease, and after a passed infection.
Due to the high rate of asymptomatic infections, clinical diagnosis of hepatitis C is difficult and screening assays are of major importance.
The Roche Elecsys anti-HCV II assay provides 100% clinical sensitivity for all known genotypes, leading to early detection of infection and patient-oriented decision making.
With high specificity in blood donors (99.84%) and samples from clinical routine, pregnant women and dialysis patients, use of the Elecsys anti-HCV II assay increases laboratory testing efficiencies.
To optimise workflows and provide operational cost savings, the ready-to-use liquid reagents have a long onboard stability of 31 days on all Roche immunoassay platforms.
The new assay complements the Roche serology assay menu that includes assays for Hepatitis A, Hepatitis B, Hepatitis C, HIV, TORCH, Herpes, Syphilis and other infectious diseases.